Connect with us


5 Top Health Care Stocks To Watch In The Stock Market Today

Are these health care stocks on your watchlist right now?
The post 5 Top Health Care Stocks To Watch In The Stock Market Today appeared first on Stock…



Should Investors Be Watching These Top Health Care Stocks This Week?

In the past 2 years, health care stocks have been among the more important sectors in the stock market thanks to the Covid-19 pandemic. Although new daily cases in the country have been relatively low compared to the start of the year, the health care industry still has many areas that could be of interest to investors. This is because of many other diseases that have high mortality rates and require extensive treatments. Health care companies have been working to develop treatments and therapies to treat these diseases. And these solutions, by extension, would mean profits for these health care companies.  

Just yesterday, the FDA approved second booster shots of the Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) Covid-19 vaccines for Americans 50 years and older. While the approval was only for those 50 years and older, the approval could potentially expand to Americans 18 years and above in the months ahead. This may happen when health regulators find that the protection from the initial booster dose has waned. Ultimately, this would mean another round of tailwinds for the two companies thanks to additional sales. And with that, here are five health care stocks to check out in the stock market today.

Health Care Stocks To Buy [Or Sell] This Week

BioNTech SE

Starting us off today, we have BioNTech, a biopharmaceutical company that has pioneered novel therapies for cancer and other serious diseases. Accordingly, the company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Based on its deep expertise in mRNA vaccine development and its in-house manufacturing capabilities, the company has created one of the first mRNA vaccines in the world to treat Covid-19.

Today, the company reported its fourth-quarter and full-year financials. Diving in, revenues for the quarter grew by over 1,000% year-over-year to $6.16 billion on strong vaccine sales. In fact, BioNTech has sold over 2.6 billion doses of its vaccine to more than 165 countries and regions worldwide in 2021. This also includes more than 1 billion doses to low- and middle-income countries. It also says that it has signed orders for 2022 delivery of up to 2.4 billion vaccine doses. Its net profit for the quarter also rose by over 700% to $3.53 billion. Also, BioNTech announced that its global Covid-19 supply chain and manufacturing network now includes 20 manufacturing facilities that span across four continents. Given the strong quarter, should investors be on the look-out for BNTX stock?

BNTX stock
Source: TD Ameritrade TOS

[Read More] 3 Top Meme Stocks To Watch In The Stock Market Today

UnitedHealth Group

UnitedHealth Group (UNH) is a multinational health care and insurance company. The company is dedicated to helping people live healthier lives and making health care work for everyone. Moreover, it offers a full spectrum of health benefit programs for individuals, employers, and Medicare and Medicaid beneficiaries. UNH also contracts directly with more than 1.3 million physicians and care professionals. Furthermore, UnitedHealth provides health benefits and delivers care to people through its health care facilities in South America.

Yesterday, the health care company said that it will be taking over LHC Group (NASDAQ: LHCG) for approximately $5.4 billion in cash. LHC, for the most part, is a provider of health care services at home, mainly for older patients dealing with chronic illness and injuries. UNH, being the largest U.S. health insurer, will further expand its footprint into home health services through this deal. Evidently, the deal will combine LHC with UNH’s Optum unit, which manages drug benefits and offers health care data analytics services. With taking over in the works, should you buy UNH stock?

UNH stock
Source: TD Ameritrade TOS


Another top health care company to watch is AstraZeneca. The company primarily focuses on three main therapy areas, Oncology, Cardiovascular & Metabolic Disease, and Respiratory. It is also selectively active in the areas of autoimmunity, neuroscience, and infection. Similar to other vaccine companies, AstraZeneca plays a vital role in providing coronavirus vaccines around the globe. Over the past year, AZN stock has risen by over 30%. On Monday, AstraZeneca said that its Evusheld long-acting antibody combination has been approved by the European Union. 

Specifically, it was approved for the prevention of Covid-19 in a broad population. It works by being taken pre-emptively and is administered in two injections. Additionally, its clinical trials showed that the drug reduces the risk of developing symptomatic Covid-19 by 77% compared to the placebo. Unlike other antibody treatments, which are used after contracting Covid-19, Evusheld would be used as an alternative vaccination for those who are immunocompromised or for whom vaccination is not recommended. Given the approval in the EU, would you invest in AZN stock?

AZN stock chart
Source: TD Ameritrade TOS

[Read More] Best Cyclical Stocks To Buy Right Now? 5 For Your List


Valneva is a biotech company that develops prophylactic vaccines for infectious diseases. In fact, it currently has several vaccines in development, including unique vaccines against Lyme disease, coronavirus, and chikungunya. The company’s portfolio also includes two commercial vaccines for travelers. The company also has approximately 700 employees across six countries. On March 24, the biotech firm reported its full-year 2021 results and shared some of its highlights. Notably, Valneva brought in total revenues of $387 million in 2021, tripling from its revenue in 2020. 

The company also shared its financial guidance for 2022. Namely, it expects to pull in between $478 to $656 million in revenue. Besides that, Valneva also made some notable strides in its clinical programs. For instance, its Lyme disease vaccine candidate VLA15 showed positive Phase 2 results. Next to that, its Covid-19 vaccine candidate VLA2001 has bagged purchase agreements from the European Commission and Bahrain. And last but not least, its Chikungunya vaccine candidate VLA1553 pre-submission process is expected to start in the second quarter this year. Considering all these, is VALN stock worth watching?

VALN stock
Source: TD Ameritrade TOS

[Read More] 4 Top Utility Stocks To Watch In April 2022

Abbott Laboratories 

Abbott is a company that specializes in a diversified line of health care products. Its products include a line of rhythm management, electrophysiology, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products. Last week, the U.S. Army awarded Abbott a $1 billion contract to provide rapid Covid-19 antigen tests to the federal government. 

Evidently, this comes as part of the Biden administration’s efforts to purchase one billion at-home test kits to help meet future testing demand. The award to Abbott, for an undisclosed quantity of its BinaxNOW and ID NOW tests, is due by June. In fact, the company’s BinaxNOW, Panbio, and ID NOW tests brought in a massive $1.6 billion in revenue during the company’s third-quarter in 2021. And throughout the full year, the total revenue from Covid test sales came in at $7.7 billion, dwarfing the $3.9 billion in 2020. With Abbott ramping up production, would you add ABT stock to your portfolio?

ABT stock
Source: TD Ameritrade TOS

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post 5 Top Health Care Stocks To Watch In The Stock Market Today appeared first on Stock Market News, Quotes, Charts and Financial Information |

Read More

Continue Reading


University of Kentucky researchers develop online portal to show how biases in RNA sequences affect gene expression

LEXINGTON, Ky. (June 29, 2022) — A recent publication from researchers at the University of Kentucky explains the importance of identifying and understanding…



LEXINGTON, Ky. (June 29, 2022) — A recent publication from researchers at the University of Kentucky explains the importance of identifying and understanding how differences between tissues and cells alter gene expression without changing the underlying genetic code.

Credit: Pete Comparoni | University of Kentucky Photo

LEXINGTON, Ky. (June 29, 2022) — A recent publication from researchers at the University of Kentucky explains the importance of identifying and understanding how differences between tissues and cells alter gene expression without changing the underlying genetic code.

Introductory biology classes teach that DNA is transcribed into RNA, which is then translated into proteins. However, many cellular processes affect how quickly transcription and translation occur. Gene expression looks at the differences in RNA concentrations within a cell, and it can help scientists know which genes are active within that tissue or cell.

“Changes in gene expression can significantly affect various diseases and disease trajectories,” said Justin Miller, Ph.D., assistant professor in the UK College of Medicine’s Department of Pathology and Laboratory Medicine.

Miller, who is also affiliated with the Sanders-Brown Center on Aging and Biomedical Informatics, says he and his colleagues previously developed the first algorithm to identify ramp sequences from a single gene sequence. Through their recent work, Miller and fellow UK co-authors Mark Ebbert, Ph.D., and Matthew Hodgman created an online version of that algorithm and showed that ramp sequences change between tissues and cells without changing the RNA sequence.

A ramp sequence is part of the RNA sequence that slows translation at the beginning of the gene by using codons (sequences of three DNA or RNA nucleotides) that are not easily translated. Ramp sequences counterintuitively increase overall gene expression by evenly spacing the translational machinery and preventing collisions later in translation.

In their recent publication in NAR Genomics and Bioinformatics, the researchers present the first comprehensive analysis of tissue- and cell type-specific ramp sequences and report more than 3,000 genes with ramp sequences that change between tissues and cell types, which correspond with increased gene expression within those tissues and cells.

“This research is the first time that variable ramp sequences have been described. Our comprehensive web interface allows other researchers to creatively explore ramp sequences and gene expression,” said Miller.

The research team says this work is important because while there are multiple ways for our RNA to encode the same proteins, the specific RNA sequence is important to regulate protein and RNA levels.

“Essentially, a ramp sequence works like an on-ramp to a freeway so that ribosomes do not crash into each other, but the length and speed limit of that onramp can change depending on the cell and the available resources within that cell,” Miller explained.

He says he enjoyed working on this project not only with his colleagues at UK but as well as his former colleagues at Brigham Young University and his brother, Kyle Miller, at Utah Valley University. Together, the group created a web interface for people to see how ramp sequences correspond with human and COVID-19 gene expression in different tissues and cells.

Miller says he believes this work will eventually impact patient care. “We created an online interface for researchers to query all human genes and see if a specific gene has a ramp sequence in a given tissue and how that gene is expressed within that tissue,” said Miller. “We also show that various COVID-19 genes and human entry factors for COVID-19 have ramp sequences that change between different tissues. Ramp sequences are much more likely to occur in tissues where the virus is known to proliferate.”

So, the researchers believe that COVID-19 genes have genetic biases (ramp sequences) that allow them to use the available cellular machinery to increase their expression. “Our research may help us better predict which tissues and cells new viruses will infect and also provides a potential therapeutic target to regulate tissue-specific gene expression without changing the translated protein,” said Miller.

Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Numbers P30AG072946 and R01AG068331, and the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM138636. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This work was also funded by the BrightFocus Foundation, under awards A2020118F and A2020161S, and the Alzheimer’s Association, under award 2019-AARG-644082.

The University of Kentucky is increasingly the first choice for students, faculty and staff to pursue their passions and their professional goals. In the last two years, Forbes has named UK among the best employers for diversity, and INSIGHT into Diversity recognized us as a Diversity Champion four years running. UK is ranked among the top 30 campuses in the nation for LGBTQ* inclusion and safety. UK has been judged a “Great College to Work for” three years in a row, and UK is among only 22 universities in the country on Forbes’ list of “America’s Best Employers.”  We are ranked among the top 10 percent of public institutions for research expenditures — a tangible symbol of our breadth and depth as a university focused on discovery that changes lives and communities. And our patients know and appreciate the fact that UK HealthCare has been named the state’s top hospital for five straight years. Accolades and honors are great. But they are more important for what they represent: the idea that creating a community of belonging and commitment to excellence is how we honor our mission to be not simply the University of Kentucky, but the University for Kentucky.

Read More

Continue Reading


White House Is Quietly Modeling For $200 Oil “Shock”

White House Is Quietly Modeling For $200 Oil "Shock"

While the Biden administration is hoping and praying that someone – anyone – will watch…



White House Is Quietly Modeling For $200 Oil "Shock"

While the Biden administration is hoping and praying that someone - anyone - will watch the comical "Jan 6" kangaroo hearsay court taking place in Congress and meant to somehow block Trump from running for president in 2024 while also making hundreds of millions of Americans forget that the current administration could very well be the worst in US history, it is quietly preparing for the worst.

As none other than pro-Biden propaganda spinmaster CNN reports, when it comes to what really matters (at least according to Gallup), namely the economy, and specifically galloping gasoline prices, the White House is in a historic shambles.

For an administration that ended last year forecasting a leveling off of 40-year high inflation and eager to tout a historically rapid recovery from the pandemic-driven economic crisis, there is a level of frustration that comes with an acutely perilous moment. Asked by CNN about progress on a seemingly intractable challenge, another senior White House official responded flatly: "Which one?"

The suspects behind the historic implosion are well known: "soaring prices, teetering poll numbers and congressional majorities that appear to be on the brink have created no shortage of reasons for unease. Gas prices are hovering at or around $5 per gallon, plastered on signs and billboards across the country as a symbolic daily reminder of the reality -- one in which White House officials are extremely aware -- that the country's view of the economy is growing darker and taking Biden's political future with it."

"You don't have to be a very sophisticated person to know how lines of presidential approval and gas prices go historically in the United States," a senior White House official told CNN.

A CNN Poll of Polls average of ratings for Biden's handling of the presidency finds that 39% of Americans approve of the job he's doing. His numbers on the economy, gas prices and inflation specifically are even worse in recent polls. What CNN won't tell you is that Biden is now polling well below Trump at this time in his tenure.

The CNN article then goes into a lengthy analysis of what is behind the current gasoline crisis (those with lots of time to kill can read it here) and also tries to explains, without actually saying it, that the only thing that can fix the problem is more supply, but - as we first explained - this can't and won't happen because green fanatics and socialist environmentalists will never agree to boosting output.

Which brings us to the punchline: as CNN's Phil Mattingly writes, "instead of managing an economy in the midst of a natural rotation away from recovery and into a stable period of growth, economic officials are analyzing and modeling worst-case scenarios like what the shock of gas prices hitting $200 per barrel may mean for the economy."

Well, in an article titled "Give us a plan or give us someone to blame", this seems like both a plan, and someone to blame.

But unfortunately for Biden - and CNN which is hoping to reset expectations - it's only going to get worse, because as we noted moments ago, while nobody was paying attention, Cushing inventories dropped to just 1 million away from operational bottoms at roughly 20MM barrels. This means that the US is officially looking at tank bottoms.

But wait, there's more... or rather, it's even worse, because as even Bloomberg's chief energy guru Javier Blas notes, over the last 2 weeks, the US gov has drained 13.7 million barrels from the SPR, "and yet, commercial oil stockpiles still fell 3 million barrels over the period."

Just imagine, Blas asks rhetorically, "if the SPR wasn't there. Or what would happen post-Oct when sales end."

And here is the punchline: at the current record pace of SPR drainage, one way or another the Biden admin will have to end its artificial attempts to keep the price of oil lower some time in October (or risk entering a war with China over Taiwan with virtually no oil reserve). This means that unless Putin ends his war some time in the next 5 months, there is a non-trivial chance that oil will hit a record price around $200 - precisely the price the White House is bracing for - a few days before the midterms. While translates into $10+ gasoline.

And while one can speculate how much longer Democrats can continue the "Jan 6" dog and pony show as the entire economy implodes around them, how America will vote in November when gas is double digits should not be a mystery to anyone.

Tyler Durden Wed, 06/29/2022 - 13:05

Read More

Continue Reading


European Commission says it doesn’t have texts between president Ursula von der Leyen and Pfizer CEO Albert Bourla

Under fire from the European ombudsman, the Commission said on Wednesday that it hasn’t found any text messages between president Ursula von der Leyen…



Under fire from the European ombudsman, the Commission said on Wednesday that it hasn’t found any text messages between president Ursula von der Leyen and Pfizer chief Albert Bourla regarding the purchase of Covid-19 vaccines.

The messages became of interest last April, when the New York Times reported that a series of texts and calls between von der Leyen and Bourla led to Pfizer’s largest vaccine deal — 900 million doses of the current vaccine and a vaccine adapted to variants, with the option to purchase an additional 900 million doses through 2023.

Emily O’Reilly

Upon a public access request made by a journalist, the EC responded that it had no record of them. However, it was later revealed by ombudsman Emily O’Reilly, the EU’s internal watchdog, that the EC never explicitly asked the cabinet to look for the texts.

Instead, the EC requested other documents that fall under its internal criteria for recording, which doesn’t include text messages.

O’Reilly accused the Commission of “maladministration,” and urged the administration to conduct a more thorough search.

“When it comes to the right of public access to EU documents, it is the content of the document that matters and not the device or form,” she said in a statement back in January. “If text messages concern EU policies and decisions, they should be treated as EU documents.”

On Wednesday, the EC claimed to side with O’Reilly: “The Commission and the Ombudsman agree that what matters is the content of a document,” a spokesperson said in an email to Endpoints News. 

However, the Commission maintained that the texts were not registered as documents “due to their short-lived and ephemeral nature.”

“Text and instant messages in general do not contain important information relating to policies, activities and decisions of the Commission, nor are they in the possession of the institution,” the EC shared in a letter.

The administration added that it intends to issue further guidance on the use of “modern communication tools” such as text and instant messages to clear up any confusion.

“The Ombudsman could equally be invited to participate in those discussions, if she wishes to do so,” the statement said.

Pfizer declined to comment on the content of the text messages.

Stella Kyriakides

The EC struck its third vaccine deal with Pfizer and BioNTech last May, after its other major supplier AstraZeneca ran into production issues and announced it would significantly reduce deliveries.

The contract, which called for up to 1.8 billion doses through 2023, also reserved the EU right to resell or donate doses to countries in need.

“We need to be one step ahead of the virus. This means having access to adapted vaccines to protect us against the threat of variants, booster vaccines to prolong immunity, as well as protecting our younger population,” commissioner for health and food safety Stella Kyriakides said at the time.

Read More

Continue Reading